|
|
|
| Study on the medication rule of traditional Chinese medicine in the treatment of breast cancer aromatase inhibitor-related osteoporosis |
| MENG Hui YU Mingwei WANG Xiaomin CHEN Yuhan ZHANG Jiahui |
| Department of Oncology, Beijing Traditional Chinese Medicine Hospital, Capital Medical University, Beijing 100010, China |
|
|
|
Abstract Objective To study the prescription medication rules of breast cancer aromatase inhibitor-related osteoporosis based on hospital information system. Methods The diagnosis and treatment information of breast cancer patients with aromatase inhibitor-related osteoporosis was collected from the information system of Beijing Traditional Chinese Medicine Hospital, Capital Medical University from January 2019 to October 2021. The overall use of traditional Chinese medicine was analyzed, and association rule analysis and cluster analysis were performed for traditional Chinese medicine. Results A total of 184 breast cancer patients with aromatase inhibitor-related osteoporosis were included. The most common traditional Chinese medicine syndroms were syndrome of healthy qi deficiency and toxin accumulation, syndrome of stagnation of liver qi and spleen deficiency, syndrome of intermin-gled phlegm and blood stasis, etc. All the prescriptions involved 298 kinds of traditional Chinese medicine, and the four nature of traditional Chinese medicine were mainly warm and calm drugs. Five flavours to sweet, bitter, bitter drugs more common. The main channel tropism of drugs was liver channel. The most frequently used drug category is the drugs for promoting blood circulation for removing blood stasis. Association rule analysis showed that the drug combinations with the highest confidence and support were Bupleuri Radix-Curcumae Radix, Atractylodis Macrocephalae Rhizoma-Herba Hedyotis-Radix, respectively. The drugs were grouped into four groups by cluster analysis. Conclusion The traditional Chinese medicine treatment of breast cancer aromatase inhibitor-related osteoporosis is to regulate liver and regulate qi, remove stasis, remove obstruction in collaterals, and relieve pain as the main treatment, supplemented by yiqi and detoxification.
|
|
|
|
|
|
[1] Early Breast Cancer Trialists’ Collaborative Group（EBCTCG）. Aromatase inhibitors versus tamoxifen in early breast cancer：patient-level meta-analysis of the randomised trials [J]. Lancet，2015，386（10001）：1341-1352.
[2] Cuzick J，Sestak I，Baum M，et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer：10-year analysis of the ATAC trial [J]. Lancet Oncol，2010，11（12）：1135-1141.
[3] Coombes RC，Kilburn LS，Snowdon CF，et al. Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment （Intergroup Exemestane Study）：a randomised controlled trial [J]. Lancet，2007，369（9561）：559- 570.
[4] 李元青，孙红，薛冬，等.舒肝健骨方防治芳香化酶抑制剂内分泌治疗相关骨丢失的临床研究[J].中国中西医结合杂志，2014，34（9）：1064-1068.
[5] 梁丽春，莫春生，李娟娟，等.补肾法对乳腺癌芳香化酶抑制剂治疗所致骨丢失的疗效观察[J].广州中医药大学学报，2019，36（3）：344-349.
[6] 瞿文超，万华，吴雪卿，等.健脾益肾法对绝经后乳腺癌芳香化酶抑制剂治疗引起骨丢失的影响[J].中国临床研究，2019，32（7）：983-985.
[7] Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis：synopsis of a WHO report. WHO Study Group [J]. Osteoporos Int，1994，4（6）：368-381.
[8] 国家药典委员会.中华人民共和国药典[M].一部.北京：中国医药科技出版社，2020：1088.
[9] Rachner TD，Coleman R，Hadji P，et al. Bone health during endocrine therapy for cancer [J]. Lancet Diabetes Endocrinol，2018，6（11）：901-910.
[10] 翁婷婷，彭海燕.中医药干预乳腺癌内分泌治疗相关性骨质疏松症现状与展望[J].中国中医药现代远程教育，2021，19（9）：193-197.
[11] Dong XL，Yu WX，Li CM，et al. Chuanxiong（Rhizome of Ligusticum chuanxiong）Protects Ovariectomized Hyperlipidemic Rats from Bone Loss [J]. Am J Chin Med，2020， 48（2）：463-485.
[12] 焦苗苗，王旭，周娜，等.延胡索、乌药、金铃子散、小活络丹对神经病理性疼痛镇痛作用的比较[J].神经药理学报，2020，10（2）：1-6.
[13] 马云飞，孙旭，念家云，等.650例康复期乳腺癌患者中医证候分布规律的横断面研究[J].中医杂志，2018，59（10）：871-875.
[14] 富琦，张青.郁仁存应用清热解毒药物治疗肿瘤经验[J].中医杂志，2014，55（21）：1815-1817.
[15] Ma TT，Zhang GL，Dai CF，et al. Scutellaria barbata and Hedyotis diffusa herb pair for breast cancer treatment：Potential mechanism based on network pharmacology [J]. J Ethnopharmacol，2020，259：112929.
[16] 梁祖建.补肾调肝法治疗高龄原发性骨质疏松症的理论、临床与实验研究[D].广州：广州中医药大学，2012.
[17] Qi X，Fan M，Huang N，et al. Saikosaponin d contributed to cancer chemotherapy induced neutropenia therapy by promoting neutrophil differentiation via activation CBL-dependent ERK pathway [J]. Pharmacol Res，2020，160：105149.
[18] Hwang YH，Jang SA，Lee A，et al. Poria Cocos Ameliorates Bone Loss in Ovariectomized Mice and Inhibits Osteoclastogenesis In Vitro [J]. Nutrients，2020，12（5）：1383.
[19] Song D，Cao Z，Tickner J，et al. Poria cocos polysaccharide attenuates RANKL-induced osteoclastogenesis by suppressing NFATc1 activity and phosphorylation of ERK and STAT3 [J]. Arch Biochem Biophys，2018，647：76-83.
[20] Lockefeer JP，De Vries J. What is the relationship between trait anxiety and depressive symptoms，fatigue，and low sleep quality following breast cancer surgery? [J]. Psychooncology，2013，22（5）：1127-1133.
[21] 李颖，魏新智.白芍不同炮制品的镇痛、镇静、抗炎作用比较[J].辽宁中医药大学学报，2016，18（4）：39-41.
[22] 王振东，曹旭阳，关智媛，等.补肾方对老年骨质疏松性椎体骨折PKP术后疼痛的影响研究[J].现代中西医结合杂志，2018，27（31）：3433-3436.
[23] 刘华，冯梓俊，邓玫，等.益气补肾汤治疗原发性骨质疏松症效果探讨[J].中国医药科学，2021，11（3）：90-92.
[24] 赵志强，阎晓霞.中药补肾法改善原发性骨质疏松症临床症状的研究[J].中国骨质疏松杂志，2018，24（3）：371- 375，410.
[25] 吴庭胜，陶志强，范少勇.应用补肾壮骨汤降低椎体成形术后再发骨折的临床疗效分析[J].中国当代医药，2021， 28（26）：84-87.
[26] 郝庆秀，王继峰，牛建昭，等.熟地等4味中药的植物雌激素作用的实验研究[J].中国中药杂志，2009，34（5）：620-624.
[27] 陈学生，张洪钦，陈秋琴，等.骨碎补总黄酮对卵巢去势大鼠骨质疏松的干预作用[J].中国当代医药，2021，28（10）：4-7，241.
[28] 李晓曦，陈宇恒，唐秀凤，等.基于雌激素作用的淫羊藿女贞子配伍对绝经后骨质疏松症大鼠的影响研究[J].中国中医骨伤科杂志，2019，27 （9）：1-6，10.
[29] 武密山，李恩，赵素芝，等.补肾方药归经与靶器官雌激素受体的相关性[J].中国临床康复，2006，10（35）：38- 41.
[30] 武密山，李恩，赵素芝，等.补肾中药靶向经穴给药对骨质疏松患者的归经调节[J].中国组织工程研究与临床康复，2007，11（27）：5336-5340. |
|
|
|
